Securities code: 600812 securities abbreviation: North China Pharmaceutical Company.Ltd(600812) No.: pro 2022-001 North China Pharmaceutical Company.Ltd(600812)
Announcement of annual performance reduction in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
According to the preliminary calculation of the financial department, the company expects to realize the net profit attributable to the shareholders of the listed company of about 20 million yuan in 2021. Compared with the same period of last year (statutory disclosure data), the company’s performance is expected to decrease by about 77.32 million yuan, a year-on-year decrease of about 79.45%.
The performance reduction of the company is mainly due to the decrease of non recurring profit and loss events such as government subsidies included in the current profit and loss, with an impact amount of about 80 million yuan.
1、 Performance forecast of the current period
(I) performance forecast period
From January 1, 2021 to December 31, 2021.
(II) performance forecast
1. According to the preliminary calculation of the financial department, the company expects to achieve a net profit attributable to the shareholders of the listed company of about 20 million yuan in 2021. Compared with the same period of last year (statutory disclosure data), the company’s performance is expected to decrease by about 77.32 million yuan, a year-on-year decrease of about 79.45%.
2. It is estimated that the net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses is about – 59 million yuan. Compared with the same period of last year (statutory disclosure data), the company’s performance is expected to increase by about 2.91 million yuan.
(III) the performance forecast of the current period has not been audited by certified public accountants.
2、 Performance in the same period of last year
(I) net profit attributable to shareholders of the listed company: 97.3238 million yuan. Net profit attributable to shareholders of the listed company after deducting non recurring profits and losses: – 61.9129 million yuan.
(II) earnings per share: 0.060 yuan.
3、 Main reasons for performance reduction in the current period
(I) main business impact.
Facing the impact of covid-19 epidemic in Gaocheng District, Shijiazhuang city and the complex situation of superposition of multiple internal and external adverse factors, the company deepened internal reform, adjusted business structure and focused on the development of biotechnology drugs and biotechnology products. It is expected that the net profit after deducting non recurring profits and losses attributable to the shareholders of the listed company is basically the same as that of the previous year.
(II) impact of non operating profit and loss.
Compared with the same period of last year, non recurring profit and loss items such as government subsidies included in the current profit and loss in this period decreased by about 80 million yuan, mainly due to the receipt of 79.44 million yuan of stabilization funds in the same period of last year. 4、 Risk tips
The company has no major uncertain factors affecting the accuracy of the performance forecast.
5、 Other explanatory matters
The above forecast data are only preliminary accounting data and have not been audited by the audit institution. The specific and accurate financial data shall be subject to the audited annual report of 2021 officially disclosed by the company. Please pay attention to the investment risks.
It is hereby announced.
North China Pharmaceutical Company.Ltd(600812)
January 14, 2022
